echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > [quick news] in December, the first 5 enterprises in 289 catalog were released

    [quick news] in December, the first 5 enterprises in 289 catalog were released

    • Last Update: 2018-12-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 5, after querying the registration and acceptance database information of smart drugs, it was found that entecavir dispersible tablets (0.5mg) of Anhui Baker biopharmaceutical Co., Ltd and amlodipine besylate (5mg (calculated according to c20h25cln2o5) of Zhejiang Jingxin Pharmaceutical Co., Ltd had been "approved pending certification" The review conclusion was approval, and 2 drugs passed the consistency evaluation According to the pharmaceutical intelligence data, 7 domestic enterprises hold the production approval documents of entecavir dispersible tablets, including 2 enterprises of Zhengda Tianqing and Suzhou Dongrui with the specification of 1.0mg and 7 enterprises with the specification of 0.5mg At present, there are four enterprises applying for the consistency evaluation of entecavir dispersible tablets, all of which have passed the specification of 0.5mg Data source: according to the bid winning situation in the registration and acceptance database of pharmaceutical intelligence, we can see that there are quite a lot of four evaluated enterprises with 0.5mg entecavir dispersible tablets in the market, including 29 winning regions of Zhengda Tianqing (after removing the repeated regions of each package ratio, the same below), 24 Jiangxi Qingfeng, 22 Suzhou dongruida, 20 Shandong Lukang medicine and 19 Anhui beckda Data source: entecavir is an oral drug for the treatment of hepatitis B virus infection It has an inhibitory effect on hepatitis B virus (HBV) polymerase At present, it is mainly used for antiviral treatment of hepatitis B, and also for the treatment of children with chronic HBV infection and compensatory liver disease between 2 and 18 years old The drug has the characteristics of rapid onset, strong resistance to hepatitis B virus and low resistance, and is the first-line antiviral treatment for chronic hepatitis B patients In addition to dispersible tablets, there are three domestic enterprises that have passed the consistency evaluation of 0.5mg entecavir capsules, namely Jiangxi Qingfeng Pharmaceutical Co., Ltd., Sichuan hisico Co., Ltd and Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd Amlodipine besylate tablet amlodipine besylate tablet is an antihypertensive drug of dihydropyridine calcium antagonists It is also used to treat chronic stable angina and variant angina At present, there are 60 domestic enterprises holding approval documents, involving three specifications of 10mg, 5mg and 2.5mg Among them, the specification listed in 289 catalog is 5mg, and 56 domestic enterprises hold the production approval documents of the specification At present, there are 18 enterprises applying for conformity assessment, 5 of which have passed the assessment, all of which are 5mg Data source: the market winning situation of amlodipine besylate tablets with a specification of 5mg in the registration and acceptance database of smart drugs is shown in the figure below At present, there are many winning regions among the five evaluated enterprises Although the Yellow River Pharmaceutical Industry in Jiangsu Province is slightly backward, it is the first evaluated enterprise and has great market potential in the future Data source: only 5 days in the database of bid winning information of smart drugs in December, 5 drugs have been evaluated and pushed! This article is the integration content, the view only represents the author, not the position of smart drugs Welcome to exchange and supplement in the message area; if you need to reprint, please note the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.